CVS Health (NYSE:CVS) had its price objective hoisted by stock analysts at Leerink Swann from $82.00 to $90.00 in a research note issued to investors on Monday. The firm currently has an “outperform” rating on the pharmacy operator’s stock. Leerink Swann’s target price indicates a potential upside of 14.72% from the stock’s current price.
CVS has been the topic of several other reports. Loop Capital lowered their price target on CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Morgan Stanley upgraded CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a research report on Friday. Needham & Company LLC lifted their price target on CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks lifted their price target on CVS Health to $90.00 and gave the company a “buy” rating in a research report on Friday. Finally, Jefferies Group decreased their target price on CVS Health from $86.00 to $76.00 and set a “hold” rating on the stock in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. CVS Health has a consensus rating of “Buy” and an average price target of $86.66.
Shares of CVS Health (NYSE CVS) traded up $3.32 during mid-day trading on Monday, hitting $78.45. The stock had a trading volume of 15,338,000 shares, compared to its average volume of 10,267,775. CVS Health has a one year low of $66.45 and a one year high of $84.72. The firm has a market cap of $79,060.00, a PE ratio of 16.21, a PEG ratio of 1.38 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.61% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVS. Westwood Holdings Group Inc. boosted its position in CVS Health by 7.1% during the first quarter. Westwood Holdings Group Inc. now owns 1,230,638 shares of the pharmacy operator’s stock valued at $96,605,000 after purchasing an additional 81,315 shares during the last quarter. Cambria Investment Management L.P. lifted its position in shares of CVS Health by 1.2% in the first quarter. Cambria Investment Management L.P. now owns 17,548 shares of the pharmacy operator’s stock worth $1,378,000 after buying an additional 214 shares during the last quarter. Barings LLC lifted its position in shares of CVS Health by 39.6% in the first quarter. Barings LLC now owns 134,319 shares of the pharmacy operator’s stock worth $10,544,000 after buying an additional 38,092 shares during the last quarter. Tudor Investment Corp ET AL lifted its position in shares of CVS Health by 106.4% in the first quarter. Tudor Investment Corp ET AL now owns 59,741 shares of the pharmacy operator’s stock worth $4,690,000 after buying an additional 30,796 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in shares of CVS Health by 1.1% in the first quarter. HighTower Advisors LLC now owns 221,664 shares of the pharmacy operator’s stock worth $17,405,000 after buying an additional 2,353 shares during the last quarter. 81.62% of the stock is owned by hedge funds and other institutional investors.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
